51
|
Nakamoto T, Ueda T, Koyama F, Nishigori N, Inoue T, Kawasaki K, Obara S, Sasaki Y, Nakamura Y, Fujii H, Nakajima Y. [A Resected Case of Cecal Cancer with Simultaneous Liver, Spleen, and Ovarian Metastasis and Peritoneal Dissemination]. Gan To Kagaku Ryoho 2016; 43:2447-2449. [PMID: 28133350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We herein report the case of a patient with a cecal cancer with simultaneous liver, spleen, and ovarian metastases as well as peritoneal dissemination who achieved a long-term survival. The patient was a 67-year-old female. Ileocecal resection with partial hepatectomy, splenectomy, simple total hysterectomy, bilateral salpingo-oophorectomy, and resection of the peritoneal dissemination were performed. The final diagnosis was Stage IV (T4a, N1, M1b[H1, P3, OTH]). Adjuvant chemotherapy was administered, but abdominal computed tomography(CT)revealed a metachronous liver metastasis 41 months later. We performed partial hepatectomy, and the patient continued adjuvant chemotherapy. The patient is currently alive and disease-free 30 months after the last operation, 72 months after the initial surgery.
Collapse
|
52
|
Obara S, Nomi T, Yamato I, Hokuto D, Yasuda S, Kawaguchi C, Yoshikawa T, Sho M, Yamada T, Akahori T, Kinoshita S, Nagai M, Kanehiro H, Nakajima Y. [Huge Hepatocellular Carcinoma with Portal Vein and Inferior Vena Cava Thrombi Treated with Curative Liver Resection and Perioperative Hepatic Arterial Infusion Chemotherapy - A Case Report]. Gan To Kagaku Ryoho 2016; 43:1779-1781. [PMID: 28133129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The prognosis of hepatocellular carcinoma(HCC)with main portal vein(MPV)and/or the inferior vena cava(IVC)tumor thrombi is dismal. The management of HCC with severe tumor thrombus is complicated. In this study, we report a case of HCC with tumor thrombi in the MPV and IVC that was successfullytreated via liver resection and perioperative hepatic arterial infusion chemotherapy(HAI). A 68-year-old man was referred to our institution to treat huge HCC lesion in the right lobe of the liver. Abdominal computed tomography(CT)revealed a tumor(12 cm in diameter)in the right hepatic lobe and tumor thrombi in the MPV and IVC. The patient was initiallytreated with HAI(cisplatin 100mg/body). After 3 courses of HAI, the tumor was dramaticallyreduced in size, and the thrombus in the IVC had disappeared; however, the thrombus in the MPV remained. Therefore, we performed right hepatectomy, wedge resection of the IVC, combined resection of the MPV, and portal vein reconstruction. The histopathological findings of the resected specimen revealed that viable cancer cells were observed onlyin an 8×8mm lesion. Subsequently, HAI was performed as adjuvant therapy for 3 courses. The patient died of other causes 2 years 3 months after surgery. There was no sign of recurrence at the time of death. This case suggested that perioperative HAI and liver resection mayrepresent an effective treatment strategyfor HCC with severe tumor thrombus.
Collapse
|
53
|
Yoshikawa T, Nomi T, Hokuto D, Yamato I, Yasuda S, Obara S, Kawaguchi C, Kinoshita S, Nishiwada S, Nagai M, Akahori T, Yamada T, Sho M, Kanehiro H, Nakajima Y. [A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment]. Gan To Kagaku Ryoho 2016; 43:1754-1756. [PMID: 28133121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The patient was a 73-year-old man, diagnosed with advanced huge hepatocellular carcinoma with a tumor thrombus extending into the inferior vena cava and extrahepatic metastases. Radiation therapy(50 Gy)was applied for the bone metastases, primary tumor, and tumor thrombus, and the patient received a cisplatin transcatheter arterial infusion(100mg/ body, 5 courses). Sorafenib was administered orally once the local lesion was under control. The tumor showed a partial response according to the RECIST criteria, but the tumor thrombus in the inferior vena cava almost disappeared. The presence of a tumor thrombus in the inferior vena cava must be regarded as an oncologic emergency. Acisplatin transcatheter arterial infusion and radiation therapy may be treatment options for unresectable cases.
Collapse
|
54
|
Nakamura Y, Koyama F, Nomi T, Yamato I, Ueda T, Hokutou D, Inoue T, Yasuda S, Kawaguchi C, Obara S, Nakamoto T, Sasaki Y, Yoshikawa T, Fujii H, Nakajima Y. [Long-Term Survival in a Case of Sigmoid Colon Cancer with Multiple Liver Metastases Treated with Repeated Hepatectomies]. Gan To Kagaku Ryoho 2016; 43:1736-1738. [PMID: 28133115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A 75-year-old man was diagnosed with sigmoid colon cancer with multiple liver metastases at our hospital in May 2010. He underwent mFOLFOX6 and panitumumab chemotherapy for 6 months. He then underwent sigmoidectomy, lymphadenectomy D3, partial resection of 2 parts of S6, and cholecystectomy in January 2011. However, he underwent partial resection of the liver an additional 4 times in the 5 years followingthe primary operation. Despite multiple liver metastases, he is alive 5 years after the primary operation, havingsurvived 5 hepatectomies for multiple resectable liver metastases.
Collapse
|
55
|
Sasaki Y, Nishigori N, Koyama F, Ueda T, Inoue T, Kawasaki K, Obara S, Nakamoto T, Nakamura Y, Fujii H, Nakajima Y. [Long-Term Survival of a Patient with Sigmoid Colon Cancer with Multiple Visceral Metastases]. Gan To Kagaku Ryoho 2016; 43:2444-2446. [PMID: 28133349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A 66-year-old woman underwent total pelvic exenteration for a pelvic tumor. The pathological diagnosis was sigmoid colon cancer T4b(in the small intestine, uterus, and vagina), N0, M0, Stage II . The patient was treated with XELOX for 6 months as adjuvant chemotherapy and was then treated with IRIS for another 6 months. Brain metastasis developed in the left occipital lobe after 12 months, and she underwent craniotomy and enucleation of the tumor. Liver metastasis and peritoneal dissemination metastasis developed 16 months after her initial diagnosis. The patient underwent re-craniotomy and radiotherapy for recurrence of the brain metastasis 18 months after diagnosis and started taking TAS-102 3 months later. She began treatment with CPT-11 plus panitumumab 24 months after diagnosis, and the dose was increased 9 months later(ie, 35 months after the initial diagnosis). The patient remains alive 42 months after surgery.
Collapse
|
56
|
Kiyomi A, Hirano T, Fujiwara N, Banba M, Rokugawa N, Nakajima Y, Sugiura M. Effects of supernatant of three-dimensional cultured breast cancer cells on regulatory T cells and programmed cell death-1 positive T cells. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
57
|
Adamson P, An FP, Anghel I, Aurisano A, Balantekin AB, Band HR, Barr G, Bishai M, Blake A, Blyth S, Bock GJ, Bogert D, Cao D, Cao GF, Cao J, Cao SV, Carroll TJ, Castromonte CM, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen R, Chen SM, Chen Y, Chen YX, Cheng J, Cheng JH, Cheng YP, Cheng ZK, Cherwinka JJ, Childress S, Chu MC, Chukanov A, Coelho JAB, Corwin L, Cronin-Hennessy D, Cummings JP, de Arcos J, De Rijck S, Deng ZY, Devan AV, Devenish NE, Ding XF, Ding YY, Diwan MV, Dolgareva M, Dove J, Dwyer DA, Edwards WR, Escobar CO, Evans JJ, Falk E, Feldman GJ, Flanagan W, Frohne MV, Gabrielyan M, Gallagher HR, Germani S, Gill R, Gomes RA, Gonchar M, Gong GH, Gong H, Goodman MC, Gouffon P, Graf N, Gran R, Grassi M, Grzelak K, Gu WQ, Guan MY, Guo L, Guo RP, Guo XH, Guo Z, Habig A, Hackenburg RW, Hahn SR, Han R, Hans S, Hartnell J, Hatcher R, He M, Heeger KM, Heng YK, Higuera A, Holin A, Hor YK, Hsiung YB, Hu BZ, Hu T, Hu W, Huang EC, Huang HX, Huang J, Huang XT, Huber P, Huo W, Hussain G, Hylen J, Irwin GM, Isvan Z, Jaffe DE, Jaffke P, James C, Jen KL, Jensen D, Jetter S, Ji XL, Ji XP, Jiao JB, Johnson RA, de Jong JK, Joshi J, Kafka T, Kang L, Kasahara SMS, Kettell SH, Kohn S, Koizumi G, Kordosky M, Kramer M, Kreymer A, Kwan KK, Kwok MW, Kwok T, Lang K, Langford TJ, Lau K, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li DJ, Li F, Li GS, Li QJ, Li S, Li SC, Li WD, Li XN, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Litchfield PJ, Littenberg L, Littlejohn BR, Liu DW, Liu JC, Liu JL, Loh CW, Lu C, Lu HQ, Lu JS, Lucas P, Luk KB, Lv Z, Ma QM, Ma XB, Ma XY, Ma YQ, Malyshkin Y, Mann WA, Marshak ML, Martinez Caicedo DA, Mayer N, McDonald KT, McGivern C, McKeown RD, Medeiros MM, Mehdiyev R, Meier JR, Messier MD, Miller WH, Mishra SR, Mitchell I, Mooney M, Moore CD, Mualem L, Musser J, Nakajima Y, Naples D, Napolitano J, Naumov D, Naumova E, Nelson JK, Newman HB, Ngai HY, Nichol RJ, Ning Z, Nowak JA, O'Connor J, Ochoa-Ricoux JP, Olshevskiy A, Orchanian M, Pahlka RB, Paley J, Pan HR, Park J, Patterson RB, Patton S, Pawloski G, Pec V, Peng JC, Perch A, Pfützner MM, Phan DD, Phan-Budd S, Pinsky L, Plunkett RK, Poonthottathil N, Pun CSJ, Qi FZ, Qi M, Qian X, Qiu X, Radovic A, Raper N, Rebel B, Ren J, Rosenfeld C, Rosero R, Roskovec B, Ruan XC, Rubin HA, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Schreiner P, Sharma R, Moed Sher S, Sousa A, Steiner H, Sun GX, Sun JL, Tagg N, Talaga RL, Tang W, Taychenachev D, Thomas J, Thomson MA, Tian X, Timmons A, Todd J, Tognini SC, Toner R, Torretta D, Treskov K, Tsang KV, Tull CE, Tzanakos G, Urheim J, Vahle P, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang X, Wang YF, Wang Z, Wang ZM, Webb RC, Weber A, Wei HY, Wen LJ, Whisnant K, White C, Whitehead L, Whitehead LH, Wise T, Wojcicki SG, Wong HLH, Wong SCF, Worcester E, Wu CH, Wu Q, Wu WJ, Xia DM, Xia JK, Xing ZZ, Xu JL, Xu JY, Xu Y, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Ye M, Ye Z, Yeh M, Young BL, Yu ZY, Zeng S, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang XT, Zhang YM, Zhang YX, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zhao QW, Zhao YB, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Limits on Active to Sterile Neutrino Oscillations from Disappearance Searches in the MINOS, Daya Bay, and Bugey-3 Experiments. PHYSICAL REVIEW LETTERS 2016; 117:151801. [PMID: 27768356 DOI: 10.1103/physrevlett.117.151801] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Indexed: 06/06/2023]
Abstract
Searches for a light sterile neutrino have been performed independently by the MINOS and the Daya Bay experiments using the muon (anti)neutrino and electron antineutrino disappearance channels, respectively. In this Letter, results from both experiments are combined with those from the Bugey-3 reactor neutrino experiment to constrain oscillations into light sterile neutrinos. The three experiments are sensitive to complementary regions of parameter space, enabling the combined analysis to probe regions allowed by the Liquid Scintillator Neutrino Detector (LSND) and MiniBooNE experiments in a minimally extended four-neutrino flavor framework. Stringent limits on sin^{2}2θ_{μe} are set over 6 orders of magnitude in the sterile mass-squared splitting Δm_{41}^{2}. The sterile-neutrino mixing phase space allowed by the LSND and MiniBooNE experiments is excluded for Δm_{41}^{2}<0.8 eV^{2} at 95% CL_{s}.
Collapse
|
58
|
An FP, Balantekin AB, Band HR, Bishai M, Blyth S, Cao D, Cao GF, Cao J, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen SM, Chen YX, Chen Y, Cheng JH, Cheng J, Cheng YP, Cheng ZK, Cherwinka JJ, Chu MC, Chukanov A, Cummings JP, de Arcos J, Deng ZY, Ding XF, Ding YY, Diwan MV, Dolgareva M, Dove J, Dwyer DA, Edwards WR, Gill R, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guan MY, Guo L, Guo RP, Guo XH, Guo Z, Hackenburg RW, Han R, Hans S, He M, Heeger KM, Heng YK, Higuera A, Hor YK, Hsiung YB, Hu BZ, Hu T, Hu W, Huang EC, Huang HX, Huang XT, Huber P, Huo W, Hussain G, Jaffe DE, Jaffke P, Jen KL, Jetter S, Ji XP, Ji XL, Jiao JB, Johnson RA, Joshi J, Kang L, Kettell SH, Kohn S, Kramer M, Kwan KK, Kwok MW, Kwok T, Langford TJ, Lau K, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li DJ, Li F, Li GS, Li QJ, Li S, Li SC, Li WD, Li XN, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu DW, Liu JL, Liu JC, Loh CW, Lu C, Lu HQ, Lu JS, Luk KB, Lv Z, Ma QM, Ma XY, Ma XB, Ma YQ, Malyshkin Y, Martinez Caicedo DA, McDonald KT, McKeown RD, Mitchell I, Mooney M, Nakajima Y, Napolitano J, Naumov D, Naumova E, Ngai HY, Ning Z, Ochoa-Ricoux JP, Olshevskiy A, Pan HR, Park J, Patton S, Pec V, Peng JC, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Raper N, Ren J, Rosero R, Roskovec B, Ruan XC, Steiner H, Sun GX, Sun JL, Tang W, Taychenachev D, Treskov K, Tsang KV, Tull CE, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Wei HY, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu CH, Wu Q, Wu WJ, Xia DM, Xia JK, Xing ZZ, Xu JY, Xu JL, Xu Y, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Ye M, Ye Z, Yeh M, Young BL, Yu ZY, Zeng S, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang XT, Zhang YM, Zhang YX, Zhang YM, Zhang ZJ, Zhang ZY, Zhang ZP, Zhao J, Zhao QW, Zhao YB, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Improved Search for a Light Sterile Neutrino with the Full Configuration of the Daya Bay Experiment. PHYSICAL REVIEW LETTERS 2016; 117:151802. [PMID: 27768341 DOI: 10.1103/physrevlett.117.151802] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Indexed: 06/06/2023]
Abstract
This Letter reports an improved search for light sterile neutrino mixing in the electron antineutrino disappearance channel with the full configuration of the Daya Bay Reactor Neutrino Experiment. With an additional 404 days of data collected in eight antineutrino detectors, this search benefits from 3.6 times the statistics available to the previous publication, as well as from improvements in energy calibration and background reduction. A relative comparison of the rate and energy spectrum of reactor antineutrinos in the three experimental halls yields no evidence of sterile neutrino mixing in the 2×10^{-4}≲|Δm_{41}^{2}|≲0.3 eV^{2} mass range. The resulting limits on sin^{2}2θ_{14} are improved by approx imately a factor of 2 over previous results and constitute the most stringent constraints to date in the |Δm_{41}^{2}|≲0.2 eV^{2} region.
Collapse
|
59
|
Hokuto D, Nomi T, Yamato I, Yasuda S, Obara S, Yoshikawa T, Kawaguchi C, Yamada T, Kanehiro H, Nakajima Y. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy. J Surg Oncol 2016; 114:959-965. [DOI: 10.1002/jso.24461] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 09/07/2016] [Indexed: 01/31/2023]
|
60
|
Hokuto D, Nomi T, Kawaguchi C, Yoshikawa T, Yasuda S, Obara S, Yamato I, Yamada T, Kanehiro H, Nakajima Y. The Administration of Celecoxib as an Analgesic after Liver Resection Is Safe. Dig Surg 2016; 34:108-113. [PMID: 27640209 DOI: 10.1159/000449042] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Accepted: 08/10/2016] [Indexed: 12/10/2022]
Abstract
BACKGROUND There are a few studies that have evaluated postoperative analgesia. The aim of this study was to evaluate the safety of administering celecoxib to manage postoperative pain after liver surgery. METHODS The cases of patients who underwent liver resection at Nara Medical University from April 2008 to December 2015 were retrospectively analyzed. From January 2013 to December 2015, celecoxib was routinely administered (600 mg/day on postoperative day (POD) 2 and 400 mg/day from POD 3-7), whereas celecoxib was not administered from April 2008 to December 2012. The patients' baseline characteristics, the operative procedures, and postoperative complications were analyzed. RESULTS In total, 207 patients were administered celecoxib (celecoxib group), whereas 246 were not (non-celecoxib group). The preoperative serum total bilirubin and creatinine levels and indocyanine green retention rate at 15 min values of the 2 groups were similar. Similar incidences of overall and major complications (Clavien-Dindo classification ≥grade IIIa) were seen in both groups (33.8 vs. 36.2%, p = 0.601 and 12.1 vs. 12.6%, p = 0.866, respectively). No significant differences in the incidences of gastrointestinal bleeding, acute renal failure, or portal vein thrombosis were observed between the groups. CONCLUSIONS The use of celecoxib for postoperative analgesia in the early period after liver resection is safe.
Collapse
|
61
|
Kawai M, Murakami Y, Motoi F, Sho M, Satoi S, Matsumoto I, Honda G, Hirono S, Okada KI, Unno M, Nakajima Y, Uemura K, Kwon AH, Fukumoto T, Kurata M, Yamaue H. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Surgery 2016; 160:293-305. [DOI: 10.1016/j.surg.2016.02.032] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 02/15/2016] [Accepted: 02/24/2016] [Indexed: 12/24/2022]
|
62
|
Sho M, Hatakeyama K, Obara S, Kunishige T, Takano M, Kasai T, Ohbayashi C, Nakajima Y. Pseudosarcomatous myofibroblastic proliferation of the gallbladder mimicking early carcinoma. Pathol Int 2016; 66:478-80. [PMID: 27349494 DOI: 10.1111/pin.12430] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 03/21/2016] [Accepted: 05/26/2016] [Indexed: 11/30/2022]
|
63
|
Kadoya N, Nakajima Y, Saito M, Miyabe Y, Kurooka M, Kito S, Sasaki M, Fujita Y, Arai K, Tani K, Yagi M, Wakita A, Tohyama N, Jingu K. TU-AB-202-01: Multi-Institutional Validation Study of Commercially Available Deformable Image Registration Software for Thoracic Images. Med Phys 2016. [DOI: 10.1118/1.4957423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
64
|
Uchida T, Kadoya N, Ichiji K, Nakajima Y, Jingu K, Osanai M, Takeda K, Takai Y, Homma N. SU-G-BRA-15: Dosimetric Evaluation of Dynamic Tumor Tracking Radiation Therapy Using Digital Phantom: A Study On Margin and Desired Accuracy of Tracking. Med Phys 2016. [DOI: 10.1118/1.4956939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
65
|
Miyasaka Y, Kadoya N, Kuroda Y, Ito K, Chiba M, Nakajima Y, Sato K, Dobashi S, Takeda K, Jingu K. TU-AB-202-02: Deformable Image Registration Accuracy Between External Beam Radiotherapy and HDR Brachytherapy CT Images for Cervical Cancer Using a 3D-Printed Deformable Pelvis Phantom. Med Phys 2016. [DOI: 10.1118/1.4957424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
66
|
Migita K, Matsumoto S, Wakatsuki K, Ito M, Kunishige T, Nakade H, Nakatani M, Kitano M, Nakajima Y. The anatomical location of the pancreas is associated with the incidence of pancreatic fistula after laparoscopic gastrectomy. Surg Endosc 2016; 30:5481-5489. [PMID: 27126620 DOI: 10.1007/s00464-016-4909-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Accepted: 04/02/2016] [Indexed: 12/23/2022]
Abstract
BACKGROUND Postoperative pancreatic fistula (POPF) is one of the major complications after laparoscopic gastrectomy (LG). We investigated the impact of the anatomical location of the pancreas, especially in relation to the suprapancreatic lymph nodes, on the incidence of POPF after LG. METHODS We retrospectively reviewed the preoperative computed tomography (CT) images of 246 patients who underwent LG with the suprapancreatic lymph node dissection between November 2008 and November 2015. The length between the levels of the pancreatic body surface and the root of the common hepatic artery (LPC) was measured on a CT image with an axial view. A receiver operating characteristics (ROC) curve analysis was performed to determine the cutoff LPC value. A multivariate analysis was performed to determine the predictive factors for POPF. RESULTS POPF occurred in 11 patients (4.5 %). The median LPC was significantly longer in the patients with POPF than in those without (26 mm vs. 21 mm, p = 0.026). The ROC curve analysis revealed that the optimal cutoff LPC value for predicting POPF was 25 mm. The POPF rate was significantly higher in the long LPC group than in the short LPC group (10 vs. 1.3 %, p = 0.002). A multivariate analysis demonstrated that a long LPC (p = 0.018) and dissection of the lymph nodes along the distal splenic artery (p = 0.042) were independent predictors of POPF. The amylase level in the drainage fluid on postoperative day 1 was significantly higher in the long LPC group than in the short LPC group. CONCLUSIONS The LPC is a simple and reliable predictor of POPF after LG. Surgeons should take the anatomical location of the pancreas into consideration when performing LG with suprapancreatic lymph node dissection.
Collapse
|
67
|
Obara S, Nomi T, Yamato I, Hokuto D, Yasuda S, Nishiwada S, Kawaguchi C, Yoshikawa T, Yamada T, Kanehiro H, Nakajima Y. Laparoscopic resection of a hepatic mucinous cystic neoplasm: A case report. Int J Surg Case Rep 2016; 24:18-21. [PMID: 27232289 PMCID: PMC4885115 DOI: 10.1016/j.ijscr.2016.04.036] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Accepted: 04/25/2016] [Indexed: 02/08/2023] Open
Abstract
The first report of a hepatic mucinous cystic neoplasm (MCN-H) completely resected by laparoscopy. MCN-H has been reported to have the potential for malignancy, and recommended to resection. Benign liver lesions including MCN-H are commonly observed in young females and lacparoscopic liver resection might have cosmetic advantages for patients.
Introduction We aimed to present a case of hepatic mucinous cystic neoplasm (MCN-H) that was completely resected by laparoscopy. Presentation of case A 47-year-old female exhibited mild elevation of serum liver enzyme levels. Abdominal computed tomography revealed a 45-mm multilocular cystic tumor in segment IV of the liver, along with intermittent border calcification and minimal wall thickness. Magnetic resonance imaging revealed fluid-to-fluid level in the cystic tumor, thereby increasing the suspicion of a mild hemorrhage. The patient underwent laparoscopic liver resection (LLR) with a diagnosis of suspected mucinous cystic neoplasm of the liver. The entire tumor was successfully resected with a laparoscopic approach. The resected specimen was a 4.2 × 3.3 × 2.2-cm cystic tumor. Histological findings revealed mucin-producing singular epithelium and ovarian-like stroma. The tumor was diagnosed as a MCN-H with no malignancy. Discussion This is the first report in which a MCN-H was completely resected by laparoscopy. MCN-H is rare and is observed in only <5% of liver cystic tumors. MCN-H has been reported to have the malignant potential. And complete resection might be a good treatment option. Along with technical development, LLR has been indicated for benign liver tumors to date. Benign liver tumors are commonly observed in young females. The smaller incisions of the laparoscopic approach might provide cosmetic advantages for patients. Conclusion We presented the first case of a MCN-H completely resected by laparoscopy. Benign tumors and tumors with malignant potential might be good indications for a laparoscopic surgery.
Collapse
|
68
|
Akahori T, Sho M, Tanaka T, Kinoshita S, Nagai M, Nishiwada S, Nishiofuku H, Ohbayashi C, Kichikawa K, Nakajima Y. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Am J Surg 2016; 211:787-92. [DOI: 10.1016/j.amjsurg.2015.10.034] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Revised: 10/15/2015] [Accepted: 10/27/2015] [Indexed: 02/07/2023]
|
69
|
Nakamura S, Sho M, Koyama F, Ueda T, Nishigori N, Inoue T, Nakamoto T, Fujii H, Yoshikawa S, Inatsugi N, Nakajima Y. Erythropoietin attenuates intestinal inflammation and promotes tissue regeneration. Scand J Gastroenterol 2016; 50:1094-102. [PMID: 25861881 DOI: 10.3109/00365521.2015.1020861] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND The prevalence of inflammatory bowel disease (IBD) is increasing. Since patients usually need long-term treatment and suffer from reduced quality of life, there is a need to develop new therapeutic strategy. The aim of this study was to investigate the therapeutic potential of erythropoietin (EPO) for the treatment of IBD. METHODS Murine colitis was induced by 3.0% Dextran Sulfate Sodium (DSS). Recombinant human EPO (rhEPO) was given to evaluate the anti-inflammatory and regenerative effects on intestinal inflammation. The effect of rhEPO on human colon epithelial cells was also evaluated. Immunohistochemical analysis of EPO receptor was performed in human IBD tissues. RESULTS While about 62% of control mice with severe colitis induced by 5-day DSS died, 85% of mice treated with rhEPO survived. Histological analysis confirmed that EPO treatment reduced the colonic inflammation. Furthermore, EPO treatment significantly downregulated the local expressions of IFN-γ, TNF-α and E-selectin in the colon, suggesting that the effect was associated with inhibiting local immune activation. In a 4-day DSS-induced colitis model, rhEPO significantly improved the recovery of body weight loss compared to controls. Furthermore, proliferating cell nuclear antigen expression was significantly upregulated in the colon tissue from mice treated with rhEPO compared to controls. In addition, rhEPO increased the growth of cultured human colon epithelial cells in a dose-dependent manner. Furthermore, EPO-receptor expression was confirmed in human IBD colon tissues. CONCLUSION Three major functions of EPO, hematopoiesis, anti-inflammation and regeneration, may produce significant effects on intestinal inflammation, therefore suggesting that rhEPO might be useful for IBD.
Collapse
|
70
|
Satoi S, Sho M, Yanagimoto H, Yamamoto T, Akahori T, Kinoshita S, Nagai M, Hirooka S, Yamaki S, Nishiwada S, Ryota H, Ikeda N, Nakajima Y, Kon M. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES 2016; 23:167-73. [DOI: 10.1002/jhbp.318] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Accepted: 01/05/2016] [Indexed: 12/28/2022]
|
71
|
An FP, Balantekin AB, Band HR, Bishai M, Blyth S, Butorov I, Cao D, Cao GF, Cao J, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen SM, Chen YX, Chen Y, Cheng JH, Cheng J, Cheng YP, Cherwinka JJ, Chu MC, Cummings JP, de Arcos J, Deng ZY, Ding XF, Ding YY, Diwan MV, Dove J, Draeger E, Dwyer DA, Edwards WR, Ely SR, Gill R, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guan MY, Guo L, Guo XH, Hackenburg RW, Han R, Hans S, He M, Heeger KM, Heng YK, Higuera A, Hor YK, Hsiung YB, Hu BZ, Hu LM, Hu LJ, Hu T, Hu W, Huang EC, Huang HX, Huang XT, Huber P, Hussain G, Jaffe DE, Jaffke P, Jen KL, Jetter S, Ji XP, Ji XL, Jiao JB, Johnson RA, Kang L, Kettell SH, Kohn S, Kramer M, Kwan KK, Kwok MW, Kwok T, Langford TJ, Lau K, Lebanowski L, Lee J, Lei RT, Leitner R, Leung KY, Leung JKC, Lewis CA, Li DJ, Li F, Li GS, Li QJ, Li SC, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin PY, Lin SK, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu DW, Liu H, Liu JL, Liu JC, Liu SS, Lu C, Lu HQ, Lu JS, Luk KB, Ma QM, Ma XY, Ma XB, Ma YQ, Martinez Caicedo DA, McDonald KT, McKeown RD, Meng Y, Mitchell I, Monari Kebwaro J, Nakajima Y, Napolitano J, Naumov D, Naumova E, Ngai HY, Ning Z, Ochoa-Ricoux JP, Olshevski A, Pan HR, Park J, Patton S, Pec V, Peng JC, Piilonen LE, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Raper N, Ren B, Ren J, Rosero R, Roskovec B, Ruan XC, Shao BB, Steiner H, Sun GX, Sun JL, Tang W, Taychenachev D, Tsang KV, Tull CE, Tung YC, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang WW, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Wei HY, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu Q, Xia DM, Xia JK, Xia X, Xing ZZ, Xu JY, Xu JL, Xu J, Xu Y, Xue T, Yan J, Yang CG, Yang L, Yang MS, Yang MT, Ye M, Yeh M, Young BL, Yu GY, Yu ZY, Zang SL, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang YM, Zhang YX, Zhang YM, Zhang ZJ, Zhang ZY, Zhang ZP, Zhao J, Zhao QW, Zhao YF, Zhao YB, Zheng L, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Measurement of the Reactor Antineutrino Flux and Spectrum at Daya Bay. PHYSICAL REVIEW LETTERS 2016; 116:061801. [PMID: 26918980 DOI: 10.1103/physrevlett.116.061801] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Indexed: 06/05/2023]
Abstract
This Letter reports a measurement of the flux and energy spectrum of electron antineutrinos from six 2.9 GWth nuclear reactors with six detectors deployed in two near (effective baselines 512 and 561 m) and one far (1579 m) underground experimental halls in the Daya Bay experiment. Using 217 days of data, 296 721 and 41 589 inverse β decay (IBD) candidates were detected in the near and far halls, respectively. The measured IBD yield is (1.55±0.04) ×10(-18) cm(2) GW(-1) day(-1) or (5.92±0.14) ×10(-43) cm(2) fission(-1). This flux measurement is consistent with previous short-baseline reactor antineutrino experiments and is 0.946±0.022 (0.991±0.023) relative to the flux predicted with the Huber-Mueller (ILL-Vogel) fissile antineutrino model. The measured IBD positron energy spectrum deviates from both spectral predictions by more than 2σ over the full energy range with a local significance of up to ∼4σ between 4-6 MeV. A reactor antineutrino spectrum of IBD reactions is extracted from the measured positron energy spectrum for model-independent predictions.
Collapse
|
72
|
Hashimoto A, Tanaka T, Sho M, Nishiofuku H, Masada T, Sato T, Marugami N, Anai H, Sakaguchi H, Kanno M, Tamamoto T, Hasegawa M, Nakajima Y, Kichikawa K. Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. Cardiovasc Intervent Radiol 2016; 39:831-9. [PMID: 26762632 DOI: 10.1007/s00270-016-1292-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 12/25/2015] [Indexed: 01/11/2023]
Abstract
PURPOSE Previous reports have shown the effectiveness of adjuvant hepatic arterial infusion chemotherapy (HAIC) in pancreatic cancer. However, percutaneous catheter placement is technically difficult after pancreatic surgery. The purpose of this study was to evaluate the feasibility and outcome of HAIC using a coaxial technique compared with conventional technique for postoperative pancreatic cancer. MATERIALS AND METHODS 93 consecutive patients who received percutaneous catheter-port system placement after pancreatectomy were enrolled. In 58 patients from March 2006 to August 2010 (Group A), a conventional technique with a 5-Fr indwelling catheter was used and in 35 patients from September 2010 to September 2012 (Group B), a coaxial technique with a 2.7-Fr coaxial catheter was used. RESULTS The overall technical success rates were 97.1 % in Group B and 86.2 % in Group A. In cases with arterial tortuousness and stenosis, the success rate was significantly higher in Group B (91.7 vs. 53.8 %; P = 0.046). Fluoroscopic and total procedure times were significantly shorter in Group B: 14.7 versus 26.7 min (P = 0.001) and 64.8 versus 80.7 min (P = 0.0051), respectively. No differences were seen in the complication rate. The 1 year liver metastasis rates were 9.9 % using the conventional system and 9.1 % using the coaxial system (P = 0.678). The overall median survival time was 44 months. There was no difference in the survival period between two systems (P = 0.312). CONCLUSIONS The coaxial technique is useful for catheter placement after pancreatectomy, achieving a high success rate and reducing fluoroscopic and procedure times, while maintaining the safety and efficacy for adjuvant HAIC in pancreatic cancer.
Collapse
|
73
|
Mathew J, Nakajima Y, Choe YK, Urabe Y, Ando W, Sato K, Shimada S. Olefin hydrosilylation catalyzed by cationic nickel(ii) allyl complexes: a non-innocent allyl ligand-assisted mechanism. Chem Commun (Camb) 2016; 52:6723-6. [DOI: 10.1039/c6cc01665k] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Cationic nickel allyl complexes catalyse selective monohydrosilylation of α-olefins with sec-silanes via a unique mechanism assisted by a non-innocent allyl ligand.
Collapse
|
74
|
Nakajima Y, Iwasaki N, Takahashi H, Yoshida M, Honda E, Kurabayashi T. MRI artifacts and radiopacity of CAD/CAM composite resin blocks. Dent Mater 2016. [DOI: 10.1016/j.dental.2016.08.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
75
|
Yanagimoto H, Satoi S, Sho M, Akahori T, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Kinoshita S, Nishiwada S, Nagai M, Ikeda N, Tsuta K, Nakajima Y, Kon M. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 2015; 77:35-41. [PMID: 26645403 DOI: 10.1007/s00280-015-2928-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 11/17/2015] [Indexed: 02/06/2023]
Abstract
BACKGROUND The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma. METHODS This phase I study used a traditional "3+3" dose-escalation design, with four dose levels. A dose-escalation schedule consisted of two doses of S-1 (60 and 80 mg/m(2) twice daily) for 2 weeks in alternate-day administration, three doses of irinotecan (125, 150, and 180 mg/m(2)) on day 1, and a single dose of oxaliplatin (85 mg/m(2)) on day 1 of a 2-week cycle. Dose-limiting toxicities (DLTs) were assessed in the first four cycles to determine the maximum tolerated dose. This clinical study was registered at UMIN000014339. RESULTS Fifteen patients received this regimen (median, eight cycles; range 4-12). At dose level 3 (S-1, 80 mg/m(2); irinotecan, 150 mg/m(2)), 2/6 patients experienced DLTs of grade 3 fatigue and grade 4 neutropenia. At dose level 4, all three patients experienced DLTs: grade 3 fatigue (n = 1) and grade 4 neutropenia (n = 2). The RD was 80, 85, and 150 mg/m(2) of S-1, oxaliplatin, and irinotecan, respectively. We found the following: response rate, 47 %; disease control rate, 80%; median progression-free survival, 6.7 months; overall survival, 13.4 months. CONCLUSIONS The SOXIRI regimen's RD is 80, 85, and 150 mg/m(2) of S-1, oxaliplatin, and irinotecan, respectively.
Collapse
|